| __timestamp | United Therapeutics Corporation | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 381287000 | 13774000 |
| Thursday, January 1, 2015 | 452612000 | 22479000 |
| Friday, January 1, 2016 | 316800000 | 27388000 |
| Sunday, January 1, 2017 | 330100000 | 35610000 |
| Monday, January 1, 2018 | 265800000 | 49007000 |
| Tuesday, January 1, 2019 | 336200000 | 61139000 |
| Wednesday, January 1, 2020 | 423900000 | 68836000 |
| Friday, January 1, 2021 | 467000000 | 97592000 |
| Saturday, January 1, 2022 | 487000000 | 106903000 |
| Sunday, January 1, 2023 | 477100000 | 120998000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for sustained growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Vericel Corporation from 2014 to 2023. Over this period, United Therapeutics consistently outspent Vericel, with its SG&A expenses peaking at approximately $487 million in 2022, a 30% increase from 2014. In contrast, Vericel's expenses grew more dramatically, surging by over 800% from $13.8 million in 2014 to $121 million in 2023. This stark difference highlights the varying scales and strategies of these companies. While United Therapeutics maintains a steady growth trajectory, Vericel's rapid increase in expenses suggests aggressive expansion efforts. Understanding these trends provides valuable insights into each company's operational focus and market strategy.
BeiGene, Ltd. vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation or Vericel Corporation: Who Invests More in Innovation?
Comparing SG&A Expenses: United Therapeutics Corporation vs Veracyte, Inc. Trends and Insights
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Neurocrine Biosciences, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Vericel Corporation
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Vericel Corporation
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.